The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2015

Filed:

Apr. 03, 2012
Applicants:

Josh Munger, Rochester, NY (US);

Bryson Bennett, Metuchen, NJ (US);

Thomas Shenk, Princeton, NJ (US);

Joshua Rabinowitz, Princeton, NJ (US);

Inventors:

Josh Munger, Rochester, NY (US);

Bryson Bennett, Metuchen, NJ (US);

Thomas Shenk, Princeton, NJ (US);

Joshua Rabinowitz, Princeton, NJ (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/38 (2006.01); A61K 31/34 (2006.01); A61K 31/335 (2006.01); A61K 31/405 (2006.01); A61K 31/225 (2006.01); A61K 31/435 (2006.01); A61K 31/522 (2006.01); A61K 31/70 (2006.01); A61K 31/24 (2006.01); A61K 31/35 (2006.01); A61K 31/365 (2006.01); A61K 31/381 (2006.01); A61K 31/336 (2006.01); A61K 31/341 (2006.01); A61K 31/351 (2006.01); A61K 31/675 (2006.01); A61K 31/706 (2006.01); A61K 31/44 (2006.01); A61K 31/22 (2006.01); A61K 31/221 (2006.01); A61K 31/52 (2006.01);
U.S. Cl.
CPC ...
A61K 31/365 (2013.01); A61K 31/351 (2013.01); A61K 31/675 (2013.01); A61K 31/706 (2013.01); A61K 31/44 (2013.01); A61K 31/22 (2013.01); A61K 31/221 (2013.01); A61K 31/522 (2013.01); A61K 31/52 (2013.01); A61K 31/405 (2013.01); A61K 31/381 (2013.01); A61K 31/336 (2013.01); A61K 31/341 (2013.01);
Abstract

Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in 'suicide' of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.


Find Patent Forward Citations

Loading…